Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy.

Jove M, Braña I, Oliva M, Hernando-Calvo A, Erasun C, Mato-Berciano A, Maliandi MV, Torres-Manjon S, Rojas LA, Connelly S, Bazan-Peregrino M, Moreno R, Martínez de Villarreal J, Real FX, Le C, Nuciforo P, Alemany R, Capellà G, Blasco C, Cascalló M, Mesía R.

Open source

DOI: 10.1158/1078-0432.ccr-26-0601
Published: 2026-09-01
Container: Clin Cancer Res
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1158/1078-0432.ccr-26-0601,
  title = {Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy.},
  author = {Jove M and  Braña I and  Oliva M and  Hernando-Calvo A and  Erasun C and  Mato-Berciano A and  Maliandi MV and  Torres-Manjon S and  Rojas LA and  Connelly S and  Bazan-Peregrino M and  Moreno R and  Martínez de Villarreal J and  Real FX and  Le C and  Nuciforo P and  Alemany R and  Capellà G and  Blasco C and  Cascalló M and  Mesía R.},
  year = {2026},
  journal = {Clin Cancer Res},
  doi = {10.1158/1078-0432.ccr-26-0601},
  url = {https://doi.org/10.1158/1078-0432.ccr-26-0601}
}

RIS

TY  - JOUR
TI  - Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy.
AU  - Jove M
AU  -  Braña I
AU  -  Oliva M
AU  -  Hernando-Calvo A
AU  -  Erasun C
AU  -  Mato-Berciano A
AU  -  Maliandi MV
AU  -  Torres-Manjon S
AU  -  Rojas LA
AU  -  Connelly S
AU  -  Bazan-Peregrino M
AU  -  Moreno R
AU  -  Martínez de Villarreal J
AU  -  Real FX
AU  -  Le C
AU  -  Nuciforo P
AU  -  Alemany R
AU  -  Capellà G
AU  -  Blasco C
AU  -  Cascalló M
AU  -  Mesía R.
PY  - 2026
JO  - Clin Cancer Res
DO  - 10.1158/1078-0432.ccr-26-0601
UR  - https://doi.org/10.1158/1078-0432.ccr-26-0601
ER  -

APA

M, J., I, B., M, O., A, H., C, E., A, M., MV, M., S, T., LA, R., S, C., M, B., R, M., J, M. D. V., FX, R., C, L., P, N., R, A., G, C., C, B., M, C., & R., M. (2026). Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy.. Clin Cancer Res. https://doi.org/10.1158/1078-0432.ccr-26-0601

Source records

europe-pmc · retrieved 2026-09-26T05:16:18.232Z